CIDRAP Antimicrobial Stewardship Project Newsletter – May 14, 2020
In this week's issue:
- What's new at CIDRAP-ASP
- RFP for TB continuity of care during COVID-19
- RFP for antimicrobial stewardship campaigns across Africa and the Middle East
- Educational materials for patients on COVID-19 medications
- Diagnostics for bacterial co-infection and AMR in COVID-19 patients
- Immunization, AMR, and COVID-19
- Effects of US fluoroquinolone black-box warning
- Spanish antibiotic use surveillance and data visualization
- Stewardship and pediatric OPAT in Australia
- AMR work during the COVID-19 lockdown in Zimbabwe
- Call for fast food commitments to reduce antibiotic use in India
- Barriers to antibiotic de-linkage in Australia
WHAT'S NEW AT CIDRAP-ASP?
[Support] CIDRAP and our Director, Michael Osterholm, PhD, MPH, have been working 7 days a week to provide news, resources, and expert commentary related to the COVID-19 pandemic, all freely accessible on our COVID-19 Resource Center. Please consider a financial contribution to our work, and thank you for helping us to continue improving health and awareness around this crucial issue!
[Weigh In] Take our May quiz to gauge your knowledge on antibiotic use for patients with sepsis. And to learn more, read a recent CIDRAP News story on broad-spectrum antibiotic use for patients with sepsis in US hospitals.
[Read] CIDRAP News recently published items on nursing home stewardship for urinary tract infections, US sepsis recommendations, and much more.
[Research] Please take a moment to visit our recently launched resource hub on COVID-19 and antimicrobial stewardship, our compendium of databases and tools for antimicrobial resistance (AMR) surveillance, our antimicrobial stewardship diagnostics resources, our database containing hundreds of publicly available clinical tools for antimicrobial stewardship programs, and our educational multimedia page. The surveillance and diagnostics pages are updated at least weekly, and we add new clinical and educational tools monthly.
[Stay Current] If you'd like to stay current on all our news and events, please follow CIDRAP-ASP on Twitter and Facebook, subscribe to our YouTube channel, and subscribe to our antimicrobial stewardship podcasts on iTunes or Spotify.
GLOBAL ANTIMICROBIAL STEWARDSHIP NEWS, EVENTS, AND RESEARCH
[Apply] Johnson & Johnson Innovation–JLABS is seeking proposals that address the continuity of care for patients with drug-resistant tuberculosis in high-burden countries during and after the COVID-19 pandemic, with proposals due soon—by May 19. And the International Society for Infectious Diseases and Pfizer announced a grant program for antimicrobial stewardship campaigns throughout Africa and the Middle East, with proposals due by Aug 4.
[Register] On May 20, the UK Royal Society of Biology will host a free online event and discussion on the One Health approach to tackling AMR and implications for the COVID-19 pandemic response, featuring presentations from Paul Hoskisson, PhD, Osman Dar, MBBS, MSc, Katharina Stärk, DrMedVet, PhD, and Becky Sugden.
[Engage] The Sinai Health System–University Health Network Antimicrobial Stewardship Program developed educational materials for patients on COVID-19 medication myths and the status of knowledge and research on drugs to prevent and manage COVID-19.
[Discover] A press release from the University of Dundee details how a team of researchers, led by James Chalmers, MBChB, PhD, has received £287,000 ($350,000 US) in funding to develop ways to rapidly diagnose bacterial co-infection and AMR in COVID-19 patients. And in Infectious Disease Special Edition, Karen Fong, PharmD, and Tristan T. Timbrook, PharmD, MBA, discuss the importance of combining the integration of rapid diagnostic testing with robust antimicrobial stewardship efforts, with particular attention to the diagnosis and management of respiratory tract infections, bloodstream infections, and sepsis.
[Rethink] In a commentary for Gavi, the Vaccine Alliance, Stephen Sosler, PhD, discusses the importance of maintaining routine immunization programs in combating the threat of rising AMR during the COVID-19 pandemic.
[Peruse] In Pharmacoepidemiology and Drug Safety, Andrew Bratsman et al found that the 2016 US Food and Drug Administration warning against using fluoroquinolones as first-line therapy for uncomplicated urinary tract infections (uUTIs), acute sinusitis, and acute bronchitis was not associated with significant changes in fluoroquinolone prescription rates at a US medical center, with most inappropriate prescriptions given to manage uUTIs.
[Learn] In commentary for the Fresh Approaches to the Study of Antimicrobials in Society project at the London School of Hygiene & Tropical Medicine, Cristina Moreno Lozano, MS, describes ongoing efforts by the Spanish Agency for Medicines to conduct national surveillance on antibiotic use and present data visually in ways that enable greater public understanding of antibiotic consumption in Spain.
[Assess] In Infectious Disease Special Edition, Marie Rosenthal, MS, highlights insights into the new guidelines on diagnosing and managing sepsis in children from guidelines co-chairs Niranjan “Tex” Kissoon, MD, Scott Weiss, MD, MSCE, and Pierre Tissieres, MD, PhD, focusing on how the guidelines affect decision-making on issues related to AMR, cardiac output, intubation, and nutrition.
[Study] In Archives of Disease in Childhood, Julie Huynh, MBBS, et al assess the implementation of an antimicrobial stewardship intervention as part of a pediatric outpatient parenteral antimicrobial therapy program in Australia, finding that the intervention was associated with reductions in inappropriately long durations of therapy.
[View] A recording of the webinar "AMR in a post-pandemic world," featuring presentations from Mirfin Mpundu, BPharm, MPH, MBA, Susan Nayiga, MSc, and Chinyere Okoro, PhD, MSc, and hosted by the London School of Hygiene & Tropical Medicine Antimicrobial Resistance Centre is now available to view. And ReAct Africa and Africa Center for Disease Control and Prevention hosted a discussion on "Reflections on post COVID-19 & global health including lessons for future responses to pandemics and antimicrobial resistance," featuring presentations from Tim Jinks, PhD, Otto Cars, MD, PhD, Patricia Geli, PhD, MPhil, MSc, Stefan Peterson, MD, PhD, and Robert Skov, MD.
[Explore] In commentary for the Fresh Approaches to the Study of Antimicrobials in Society project at the London School of Hygiene & Tropical Medicine, Faith Kandiye describes the status of work on AMR during the COVID-19 lockdown in Zimbabwe.
[Analyze] In Open Forum Infectious Diseases, Michael Dagher, MD, et al review arguments for and against oral antibiotics to complete treatment of uncomplicated Staphylococcus aureus bacteremia, concluding that oral step-down therapy may be appropriate for patients who meet the criteria for uncomplicated infections and will comply with outpatient follow-up.
[Examine] On DownToEarth, Rajeshwari Sinha, PhD, MSc, and Amit Khurana, discuss how antibiotic use policy varies across Indian fast-food restaurants, arguing for India-specific time-bound public commitments to eliminate non-therapeutic use of medically important antibiotics in animals. And the Swedish International Agricultural Network Initiative explores interdisciplinary efforts to elevate the issue of AMR and antibiotic use in agriculture on the national and international decision-making agenda.
[Evaluate] In a perspective piece for the British Society for Antimicrobial Chemotherapy, Ronan McCarthy, PhD, describes the potential for a rise in AMR associated with the COVID-19 pandemic, calling for a unified global effort, industry incentives, and large-scale funding to address the problem. And in the Tribune Review, Cornelius Clancy, MD, describes the connection between the need for new antibiotics and the care of COVID-19 patients.
[Review] In Clinical Infectious Diseases, Kimberly E. Hanson, MD, MHS, et al describe decision-making scenarios using patient-centered vignettes and rapid molecular testing methods for diagnosing acute respiratory tract infections. And in JAC–Antimicrobial Resistance, Nadine T. Hillock, BPharm, MPH, et al held interviews with 18 stakeholders about the de-linkage of antibiotic reimbursement from sales in Australia, finding that barriers included the country's current medicines funding structure across different levels of government and the need for evidence on funding in public versus private healthcare settings.